Compare WT & WGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | WT | WGS |
|---|---|---|
| Founded | 1985 | 2017 |
| Country | United States | United States |
| Employees | N/A | 1300 |
| Industry | Investment Bankers/Brokers/Service | Retail: Computer Software & Peripheral Equipment |
| Sector | Finance | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4B | 2.6B |
| IPO Year | 2011 | N/A |
| Metric | WT | WGS |
|---|---|---|
| Price | $13.88 | $57.52 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 7 |
| Target Price | $16.75 | ★ $140.71 |
| AVG Volume (30 Days) | ★ 2.2M | 679.7K |
| Earning Date | 05-01-2026 | 04-29-2026 |
| Dividend Yield | ★ 0.82% | N/A |
| EPS Growth | ★ 127.27 | N/A |
| EPS | ★ 0.75 | N/A |
| Revenue | ★ $493,753,000.00 | N/A |
| Revenue This Year | $35.32 | $29.98 |
| Revenue Next Year | $8.08 | $26.04 |
| P/E Ratio | ★ $19.43 | $1,251.58 |
| Revenue Growth | ★ 15.43 | N/A |
| 52 Week Low | $7.47 | $55.17 |
| 52 Week High | $17.68 | $170.87 |
| Indicator | WT | WGS |
|---|---|---|
| Relative Strength Index (RSI) | 38.84 | 27.96 |
| Support Level | $13.07 | N/A |
| Resistance Level | $14.96 | $95.75 |
| Average True Range (ATR) | 0.61 | 4.43 |
| MACD | -0.13 | -1.25 |
| Stochastic Oscillator | 17.84 | 5.64 |
WisdomTree Inc is a financial innovator, offering a diverse suite of Exchange-traded products (ETPs), models and solutions, private market investments and digital asset-related products. It also offers digital products and services related to tokenized real world assets and stablecoins, including tokenized mutual funds (Digital Funds), as well as its institutional platform, WisdomTree Connect, and blockchain-native digital wallet, WisdomTree Prime. The company's products are distributed across various asset management industry channels, including banks, brokerage firms, registered investment advisers, institutional investors, private wealth managers and online brokers. The majority of the company's revenue is generated from advisory fees earned from ETPs.
GeneDx Holdings Corp focuses on genomics, creating the foundation for providing genomic information at scale and pioneering exome and genome sequencing for rare and ultra-rare genetic pediatric disorders. The company believes exome and genome testing will become the standard for diagnosing genetic disease, with the potential to transform healthcare from reactive to proactive. It aims to advance precision medicine by offering genetic diagnoses at the earliest moments, driving improved outcomes, and fueling discovery with genomic intelligence. Its operating segment mainly provides pediatric and rare disease diagnostics, focusing on whole exome and genome sequencing and, to a lesser extent, data and information services.